Learn more about whether Legend Biotech Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics ... cancer testing kits have been particularly strong performers as of late. Argus has a "buy" rating and ...

Learn more about whether Twist Bioscience Corporation or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Shares of CRISPR Therapeutics CRSP have lost more than ... sector’s downturn have left investors confused about whether to buy, hold, or sell the stock. Let’s delve into the company’s ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past ... and the drug/biotech sector’s downturn have left investors confused about whether to buy, hold, or sell the stock. Let’s ...